BOTOX® Cosmetic  Selects This Year's Entrepreneurs for The Confidence Project

BOTOX® Cosmetic Selects This Year's Entrepreneurs for The Confidence Project

 
 
  • Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp"
  •  
  • Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX ® Cosmetic
  •  

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs . This initiative, led by BOTOX ® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country.

 

This year's participants were selected from a pool of applicants representing a wide range of industries, backgrounds, and business ideas. BOTOX ® Cosmetic invited these business owners to participate in a Virtual Community Summit earlier this month centered around business development, camaraderie, and financial coaching. Following the summit, each entrepreneur is set to begin an intensive "Boostcamp" powered by Hello Alice, an online platform that helps businesses launch and grow. The Boostcamp is designed to provide business owners with practical tools, mentorship, and education to help them scale their venture with confidence.

 

"On behalf of BOTOX ® Cosmetic and everyone at Allergan Aesthetics, I am proud to welcome this new group of entrepreneurs to The Confidence Project," said Nicole Katz , Vice President, Customer Engagement and Corporate Affairs at Allergan Aesthetics. "As the leader in aesthetics, we know what's possible when preparation and confidence are met with opportunity. We are honored to support this year's class of entrepreneurs. BOTOX ® Cosmetic is committed to building a future where women entrepreneurs have resources to forge new paths and propel their businesses to success."

 

Following the Boostcamp, select entrepreneurs will be chosen to participate in a Pitch Lab to present their business to a grant selection committee. Ultimately, 20 business owners will be selected and will each receive a $20,000 grant from BOTOX ® Cosmetic to help make their business goals a reality. The selection panel is comprised of Allergan Aesthetics executives and aesthetic entrepreneurs, including Shawna Chrisman , Board-Certified Nurse Practitioner and Founder of Destination Aesthetics Medical Spa™; Nicci Levy , CEO and Founder of ALCHEMY 43; and Caroline Robinson , MD, FAAD, Board-Certified Dermatologist and Founder of Tone Dermatology.

 

"As a founder and entrepreneur, I know firsthand how critical community is when building a successful business. The opportunity to participate in The Confidence Project since the beginning has been deeply inspiring," said Shawna Chrisman . "These entrepreneurs aren't just growing companies; they're reshaping industries and bettering communities."

 

The 20 grant recipients will be announced in October 2025 . For more information on The Confidence Project, visit www.botoxcosmetic.com/realimpact and follow @botoxcosmetic on Instagram and YouTube where participants will be featured in the coming months.

 

  About Allergan Aesthetics  
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com .

 

  About AbbVie  
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn   ,   Facebook , Instagram , X (formerly Twitter) , and YouTube .

 

  Approved Uses  
BOTOX ® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.

 

  IMPORTANT SAFETY INFORMATION  

 

  BOTOX   ® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX   ® Cosmetic:  

 
  •   Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
  •  
  •   Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
  •  

  BOTOX   ® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.  

 

There has not been a confirmed serious case of spread of toxin effect when BOTOX ® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

 

BOTOX ® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX ® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.  

 

  Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

 

  Do not receive BOTOX   ® Cosmetic if you are allergic to any of the ingredients in BOTOX ® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

 

  Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX ® Cosmetic.

 

  Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX ® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX ® Cosmetic passes into breast milk).

 

  Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX ® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX   ® Cosmetic in the past.  

 

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

 

  Other side effects of BOTOX   ® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

 

For more information, refer to the Medication Guide or talk with your doctor.

 

To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.
Please see BOTOX ® Cosmetic full Prescribing Information , including Boxed Warning and Medication Guide .  

 

© 2025 AbbVie. All rights reserved. BOTOX Cosmetic and its designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates.

 

  Contacts:  

 

Investors:
Liz Shea  
Liz.Shea@AbbVie.com  
(847) 935-2211

 

Media:
Ember Garrett
Ember.Garrett@allergan.com  
(714) 246-3525

 
 

  

 
 

 

 
 

  BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project 

 

  Allergan Aesthetics (PRNewsfoto/AbbVie) 

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-selects-this-years-entrepreneurs-for-the-confidence-project-302510168.html  

 

SOURCE AbbVie

 
 

 

News Provided by PR Newswire via QuoteMedia

ABBV:US
The Conversation (0)
AbbVie Inc.

AbbVie Inc.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×